EcoR1 Capital Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Growth-stage crossover fund investing in life sciences companies from late-stage private rounds through public equity. Named after the EcoR1 restriction enzyme, reflecting the firm's scientific roots. Focuses on platform technologies and novel therapeutic modalities.
EcoR1 Capital is a $5B biotech-focused hedge fund managed by Oleg Nodelman. As of their latest 13F filing (Q2 2026), the fund holds 30 positions worth $2.0B. This quarter they initiated 8 new positions and exited 88. Their largest holding is ZYME ($600.4M).
EcoR1 initiated 8 new positions and increased 4 this quarter. Portfolio shrank -13.8% to $2.0B. 273 upcoming catalysts across holdings.
Portfolio Value (13F)
$2.0B
Holdings
30
Top 10 Concentration
88.0%
QoQ Change
-13.8%
Turnover
7.3%
Portfolio Value Trend
Be first to know when EcoR1 Capital files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc. | $600.4M | 29.77% | 9.6% | ||
| 2 | ANAB | AnaptysBio Inc. | $531.9M | 26.38% | 40.0% | ||
| 3 | AKTS | Aktis Oncology, Inc. | $155.5M | 7.71% | 21.3% | ||
| 4 | CGON | CG Oncology, Inc. | Increased↑3Q | $106.2M | 5.26% | 12.9% | |
| 5 | ETON | Eton Pharmaceuticals, Inc. | $78.6M | 3.90% | 6.9% | ||
| 6 | CRSP | CRISPR Therapeutics AG | $75.8M | 3.76% | 27.0% | ||
| 7 | ORIC | ORIC Pharmaceuticals Inc. | $72.9M | 3.61% | 17.9% | ||
| 8 | FHN-PH | First Horizon Corp. | New | $63.9M | 3.17% | — | — |
| 9 | GLPGF | Galapagos NV | $50.0M | 2.48% | — | ||
| 10 | NGNE | Neurogene Inc. | $40.0M | 1.98% | 18.0% |
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 30 holdings (you're viewing the top 10), plus 12 quarters of position history.
No charge for 14 days · Cancel anytime
EcoR1 Capital held 30 biotech stocks in their 13F portfolio this quarter. Their top positions include ZYME, ANAB, AKTS, CGON, ETON. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
EcoR1 Capital's tracked biotech portfolio is worth $2.0B across 30 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
EcoR1 Capital initiated 8 new positions this quarter, including FHN-PH, FULC, LEGN, AURA, ODTX and 3 more. They also increased 4 existing positions.
EcoR1 Capital fully exited 88 positions this quarter, including MDGL, KURA, MNKD, BCYC, ITOS and 83 more. They also trimmed 4 existing positions.
Growth-stage crossover fund investing in life sciences companies from late-stage private rounds through public equity. Named after the EcoR1 restriction enzyme, reflecting the firm's scientific roots. Focuses on platform technologies and novel therapeutic modalities.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial